https://orcid.org/0000-0001-7795-9939
References
- Naik RP, Streiff MB, Haywood C, et al. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med. 2013;126(5):443–449.
- Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica. 2019;94(11):1481–1484.
- Stein PD, Beemath A, Meyer FA, et al. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med. 2006;119(10):897.e7–11.
- Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients. Chest. 2012;141(2 Suppl):e195S–e226S.
- Schunemann HJ, Cushman M, Barnett AE, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patient. Blood Adv. 2018;2(22):3198–3225.
- Kelley D, Jones LT, Wu J, et al. Evaluating the safety and effectiveness of venous thromboembolism in prophylaxis in patients with sickle cell disease. J Thromb Thrombolysis. 2017;43(4):463–468.
- Lau BD, Wang J, Hobson DB, et al. Missed doses of venous thromboembolism prophylaxis: a growing problem without an active management strategy. J Gen Inter Med. 2021;36(2):540–542.
- Poopla VO, Tavakoli F, Lau BD, et al. Exploring the impact of route of administration on medication acceptance in hospitalized patients: implications for venous thromboembolism prevention. Thromb Res. 2017;160:109–113.
- Shermock KM, Lau BD, Haut ER, et al. Patterns of non-administration of ordered doses of venous thromboembolism prophylaxis: implications for novel intervention strategies. PLoS One. 2013;8(6):e66311. 14
- Crego N, Douglas C, Bonnabeau E, et al. Sickle-cell disease co-management, health care utilization, and hydroxyurea use. The Journal of the American Board of Family Medicine. 2020;33:91–105.
- Hamideh D, Alvarez O. Sickle cell disease related mortality in the United States (1999-2009). Pediatr Blood Cancer. 2013;60(9):1482–1486.
- Alkindi S, Al-Ghadani AR, Al-Zeheimi SR, et al. Predicting risk factors for thromboembolic complications in patients with sickle cell anaemia-lessons learned for prophylaxis. J Int Med Res. 2021;49(12):3000605211055385.
- Janz NK. The health belief model: a decade later. Health Educ Behav. 1984;11:1–47.
- Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513–523.
- Key NS, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;35(5):496–520.
- Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e278S–e325S.
- Wong A, Krause PS, Lau BD, et al. Patient preferences regarding pharmacologic venous thromboembolism prophylaxis. J Hosp Med. 2015;10(2):108–111.
- Kreutzer L, Yang AD, Sansone C, et al. Barriers to providing VTE chemoprophylaxis to hospitalized patients: a nursing-focused qualitative evaluation. J Hosp Med. 2019;14(11):668–672.
- Elder S, Hobson DB, Rand CS, et al. Hidden barriers to delivery of pharmacological venous thromboembolism prophylaxis: the role of nursing beliefs and practices. J Patient Saf. 2016;12(2):63–68.